Citations

Clear

6273 citation(s) found for "To, Andrew".

Motor end‐plate fine structure in acrylamide dying‐back neuropathy
TSUJIHATA, MlTSUHlRO, Engel, Andrew G. , Lambert, Edward H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 24 | Issue: 9 | Pages: 849-849

10.1212/wnl.24.9.849 | PMID 4368933 Get It

Progressive ataxia, retinal degeneration, neuromyopathy, and mental subnormality in a patient with true hypoparathyroidism, dwarfism, malabsorption, and cholelithiasis
Gómez, Manuel R., Engel, Andrew G. , Dyck, P. James B.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 22 | Issue: 8 | Pages: 849-849

10.1212/wnl.22.8.849 | PMID 4673413 Get It

Histometric study of neuromuscular junction ultrastructure
Santa, Tetsuji, Engel, Andrew G. , Lambert, Edward G.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 22 | Issue: 4 | Pages: 370-370

10.1212/wnl.22.4.370 | PMID 4335874 Get It

Histometric study of neuromuscular junction ultrastructure
Santa, Tetsuji, Engel, Andrew G. , Lambert, Edward H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 22 | Issue: 1 | Pages: 71-71

10.1212/wnl.22.1.71 | PMID 4333030 Get It

Emetine myopathy
Duane, Drake D. , Engel, Andrew G.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 20 | Issue: 8 | Pages: 733-733

10.1212/wnl.20.8.733 | PMID 4195358 Get It

Calcium activation of electrically inexcitable muscle fibers in primary hypokalemic periodic paralysis
Engel, Andrew G. , Lambert, Edward H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 19 | Issue: 9 | Pages: 851-851

10.1212/wnl.19.9.851 | PMID 5816878 Get It

Studies on carbohydrate metabolism and mitochondrial respiratory activities in primary hypokalemic periodic paralysis
Engel, Andrew G. , Potter, Clarence S., Rosevear, John W.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 17 | Issue: 4 | Pages: 329-329

10.1212/wnl.17.4.329 | PMID 6067069 Get It

The spectrum and diagnosis of acid maltase deficiency
Engel, Andrew G. , Gómez, Manuel R., Seybold, Marjorie E., Lambert, Edward H.

Mayo Clinic

Neurology | May 13, 2012 | Volume: 23 | Issue: 1 | Pages: 95-95

10.1212/wnl.23.1.95 | PMID 4510595 Get It

An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma
Vij, Ravi , Wang, Michael , Stewart, A. Keith, Kukreti, Vishal , McDonagh, Kevin T., Alsina, Melissa , Reu, Frederic J. , Gabrail, Nashat , Belch, Andrew R. , Matous, Jeffrey, Lee, Peter P. , Rosen, Peter J., Sébag, Michaël , Vesole, David H., Kunkel, Lori, Wear, Sandra, Orlowski, Robert Z. , Kaufman, Jonathan L. , Lonial, Sagar , Jakubowiak, Andrzej , Jagannath, Sundar , Bahlis, Nizar Jacques , Wong, Alvin , Orlowski, Robert Z. , Siegel, David S. , Reu, Frederic J

Mayo Clinic

Blood | May 4, 2012 | Volume: 119 | Issue: 24 | Pages: 5661-5670

10.1182/blood-2012-03-414359 | PMID 22555973 Get It

Abstract Carfilzomib is a selective proteasome inhibitor that binds irreversibly to its target. In phase 1 studies, carfilzomib elicited promising responses and an acceptable toxicity profile in patients with relapsed and/or refractory multiple myeloma (R/R MM). In the present phase 2, multicenter, open-label study, 129 bortezomib-naive patients with R/R MM (median of 2 prior therapies) were separated into Cohort 1, scheduled to receive intravenous carfilzomib 20 mg/m2 for all treatment cycles, and Cohort 2, scheduled to receive 20 mg/m2 for cycle 1 and then 27 mg/m2 for all subsequent cycles. The primary end point was an overall response rate (≥ partial response) of 42.4% in Cohort 1 and 52.2% in Cohort 2. The clinical benefit response (overall response rate + minimal response) was 59.3% and 64.2% in Cohorts 1 and 2, respectively. Median duration of response was 13.1 months and not reached, and median time to progression was 8.3 months and not reached, respectively. The most common treatment-emergent adverse events were fatigue (62.0%) and nausea (48.8%). Single-agent carfilzomib elicited a low incidence of peripheral neuropathy—17.1% overall (1 grade 3; no grade 4)—in these pretreated bortezomib-naive patients. The results of the present study support the use of carfilzomib in R/R MM patients. This trial is registered at www.clinicaltrials.gov as NCT00530816.
Reversible Paraneoplastic Tonic Pupil with PCA-Tr IgG and Hodgkin Lymphoma
Horta, Erika , McKeon, Andrew , Lennon, Vanda A. , Benarroch, Eduardo E. , McKeon, Andrew

Mayo Clinic

Neurology | May 3, 2012 | Volume: 78 | Issue: 20 | Pages: 1620-1622

10.1212/wnl.0b013e3182563b9b | PMID 22551727 Get It